Wenshuang Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wenshuang Wu has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Haoyu Ye
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
9 shared publications Minghai Tang
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China
9 shared publicationsZhichao Xing
Division of Thyroid Surgery, Department of General Surgery and Laboratory of Thyroid and Parathyroid Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China
9 shared publicationsNa Li
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China
8 shared publicationsKaiyue Su
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
7 shared publicationsLi Mi
Division of Thyroid Surgery, Department of General Surgery and Laboratory of Thyroid and Parathyroid Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China
7 shared publications
Latest Publications
- 6 April 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 179, 116605
Post-translational modifications of gasdermin D: implications for pyroptosis and autoimmune diseases
- 6 April 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 179, 116605
Post-translational modifications of gasdermin D: implications for pyroptosis and autoimmune diseases
- 9 May 2025
- Published by Elsevier in Phytomedicine
- Vol. 143, 156835
Valtrate alleviates inflammation by targeting USP9X to enhance NLRP3 degradation
- 9 May 2025
- Published by Elsevier in Phytomedicine
- Vol. 143, 156835
Valtrate alleviates inflammation by targeting USP9X to enhance NLRP3 degradation
- Open Access
- 8 May 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (19)
VCP’s nuclear journey: Initiated by interacting with KPNB1 to repair DNA damage
DNA damage repair (DDR) is essential for cancer cell survival and treatment resistance, making it a critical target for tumor therapy. The eukaryotic AAA+ adenosine triphosphatase valosin-containing protein (VCP), which is transported from the cytoplasm into the nucleus, plays a critical role in the DDR process. However, the nuclear translocation and molecular mechanism of VCP for DDR remain elusive. Here, we define VCP as a KPNB1 interacting protein through a combination of chemical and immunoprecipitation mass spectrometry approaches. Further biochemical studies elucidate that KPNB1 directly transports VCP into the nucleus. We also identify withaferin A (WA) as a small molecule that can retard VCP nuclear localization via covalent binding to CYS 158 of KPNB1. Further studies verify WA as an effective antitumor drug candidate via blocking VCP nuclear localization to impact on the DDR pathway in vivo. Our findings underly the unclear VCP’s role in DDR in a KPNB1-dependent manner and provide an important theoretical basis for developing small-molecule inhibitors targeting this process.
- 8 May 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (19)
Open AccessVCP’s nuclear journey: Initiated by interacting with KPNB1 to repair DNA damage
DNA damage repair (DDR) is essential for cancer cell survival and treatment resistance, making it a critical target for tumor therapy. The eukaryotic AAA+ adenosine triphosphatase valosin-containing protein (VCP), which is transported from the cytoplasm into the nucleus, plays a critical role in the DDR process. However, the nuclear translocation and molecular mechanism of VCP for DDR remain elusive. Here, we define VCP as a KPNB1 interacting protein through a combination of chemical and immunoprecipitation mass spectrometry approaches. Further biochemical studies elucidate that KPNB1 directly transports VCP into the nucleus. We also identify withaferin A (WA) as a small molecule that can retard VCP nuclear localization via covalent binding to CYS 158 of KPNB1. Further studies verify WA as an effective antitumor drug candidate via blocking VCP nuclear localization to impact on the DDR pathway in vivo. Our findings underly the unclear VCP’s role in DDR in a KPNB1-dependent manner and provide an important theoretical basis for developing small-molecule inhibitors targeting this process.
- 14 April 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 291, 117638
Potential therapeutic targets of eukaryotic translation initiation factors in tumor therapy
- 14 April 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 291, 117638
Potential therapeutic targets of eukaryotic translation initiation factors in tumor therapy
- 2 March 2025
- Published by Elsevier in Autoimmunity Reviews
- Vol. 24 (6) , 103783
The immune system in Hashimoto's thyroiditis: Updating the current state of knowledge on potential therapies and animal model construction
- 2 March 2025
- Published by Elsevier in Autoimmunity Reviews
- Vol. 24 (6) , 103783
The immune system in Hashimoto's thyroiditis: Updating the current state of knowledge on potential therapies and animal model construction
- Open Access
- 4 October 2024
- Published by Elsevier in Pharmacological Research
- Vol. 209, 107449
Harnessing natural inhibitors of protein synthesis for cancer therapy: A comprehensive review
- 4 October 2024
- Published by Elsevier in Pharmacological Research
- Vol. 209, 107449
Open AccessHarnessing natural inhibitors of protein synthesis for cancer therapy: A comprehensive review
- 28 April 2024
- Published by Elsevier in Phytomedicine
- Vol. 129, 155670
The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy
- 28 April 2024
- Published by Elsevier in Phytomedicine
- Vol. 129, 155670
The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy
- Open Access
- 9 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (6) , eadi9284
NU6300 covalently reacts with cysteine-191 of gasdermin D to block its cleavage and palmitoylation
Gasdermin D (GSDMD) serves as a vital mediator of inflammasome-driven pyroptosis. In our study, we have identified NU6300 as a specific GSDMD inhibitor that covalently interacts with cysteine-191 of GSDMD, effectively blocking its cleavage while not affecting earlier steps such as ASC oligomerization and caspase-1 processing in AIM2- and NLRC4-mediated inflammation. On the contrary, NU6300 robustly inhibits these earlier steps in NLRP3 inflammasome, confirming a unique feedback inhibition effect in the NLRP3-GSDMD pathway upon GSDMD targeting. Our study reveals a previously undefined mechanism of GSDMD inhibitors: NU6300 impairs the palmitoylation of both full-length and N-terminal GSDMD, impeding the membrane localization and oligomerization of N-terminal GSDMD. In vivo studies further demonstrate the efficacy of NU6300 in ameliorating dextran sodium sulfate–induced colitis and improving survival in lipopolysaccharide-induced sepsis. Overall, these findings highlight the potential of NU6300 as a promising lead compound for the treatment of inflammatory diseases.
- 9 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (6) , eadi9284
Open AccessNU6300 covalently reacts with cysteine-191 of gasdermin D to block its cleavage and palmitoylation
Gasdermin D (GSDMD) serves as a vital mediator of inflammasome-driven pyroptosis. In our study, we have identified NU6300 as a specific GSDMD inhibitor that covalently interacts with cysteine-191 of GSDMD, effectively blocking its cleavage while not affecting earlier steps such as ASC oligomerization and caspase-1 processing in AIM2- and NLRC4-mediated inflammation. On the contrary, NU6300 robustly inhibits these earlier steps in NLRP3 inflammasome, confirming a unique feedback inhibition effect in the NLRP3-GSDMD pathway upon GSDMD targeting. Our study reveals a previously undefined mechanism of GSDMD inhibitors: NU6300 impairs the palmitoylation of both full-length and N-terminal GSDMD, impeding the membrane localization and oligomerization of N-terminal GSDMD. In vivo studies further demonstrate the efficacy of NU6300 in ameliorating dextran sodium sulfate–induced colitis and improving survival in lipopolysaccharide-induced sepsis. Overall, these findings highlight the potential of NU6300 as a promising lead compound for the treatment of inflammatory diseases.
- Open Access
- 1 October 2023
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 42 (4) , 518-531
Diagnostic performance of ultrasound risk stratification systems on thyroid nodules cytologically classified as indeterminate: a systematic review and meta-analysis
Purpose: Ultrasound (US) risk stratification systems (RSSs) are increasingly being utilized for the optimal management of thyroid nodules, including those with indeterminate cytology. The goal of this study was to evaluate the category-based diagnostic performance of US RSSs in identifying malignancy in indeterminate nodules.Methods: This systematic review and meta-analysis was registered on PROSPERO (CRD42021266195). PubMed, EMBASE, and Web of Science were searched through December 1, 2022. Original articles reporting data on the performance of US RSSs for indeterminate nodules were included. The numbers of nodules classified as true negative, true positive, false negative, and false positive were extracted.Results: Thirty-three studies evaluating 7,225 indeterminate thyroid nodules were included. The diagnostic accuracy was quantitatively synthesized using a Bayesian bivariate model based on the integrated nested Laplace approximation in R. For the intermediate- to high-risk category, the sensitivity levels of the American College of Radiology, the American Thyroid Association, the European Thyroid Association, the Korean Thyroid Association/Korean Society of Thyroid Radiology, and Kwak et al. were found to be 0.80, 0.72, 0.76, 0.96, and 0.97, respectively. The corresponding specificity measurements were 0.36, 0.50, 0.49, 0.28, and 0.17. Furthermore, for the high-risk category, the sensitivity values were 0.40, 0.46, 0.55, 0.47, and 0.10, while the specificity levels were 0.91, 0.90, 0.71, 0.91, and 0.99, respectively.Conclusion: The overall diagnostic performance of the US RSSs was moderate in the differentiation of indeterminate nodules.
- 1 October 2023
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 42 (4) , 518-531
Open AccessDiagnostic performance of ultrasound risk stratification systems on thyroid nodules cytologically classified as indeterminate: a systematic review and meta-analysis
Purpose: Ultrasound (US) risk stratification systems (RSSs) are increasingly being utilized for the optimal management of thyroid nodules, including those with indeterminate cytology. The goal of this study was to evaluate the category-based diagnostic performance of US RSSs in identifying malignancy in indeterminate nodules.Methods: This systematic review and meta-analysis was registered on PROSPERO (CRD42021266195). PubMed, EMBASE, and Web of Science were searched through December 1, 2022. Original articles reporting data on the performance of US RSSs for indeterminate nodules were included. The numbers of nodules classified as true negative, true positive, false negative, and false positive were extracted.Results: Thirty-three studies evaluating 7,225 indeterminate thyroid nodules were included. The diagnostic accuracy was quantitatively synthesized using a Bayesian bivariate model based on the integrated nested Laplace approximation in R. For the intermediate- to high-risk category, the sensitivity levels of the American College of Radiology, the American Thyroid Association, the European Thyroid Association, the Korean Thyroid Association/Korean Society of Thyroid Radiology, and Kwak et al. were found to be 0.80, 0.72, 0.76, 0.96, and 0.97, respectively. The corresponding specificity measurements were 0.36, 0.50, 0.49, 0.28, and 0.17. Furthermore, for the high-risk category, the sensitivity values were 0.40, 0.46, 0.55, 0.47, and 0.10, while the specificity levels were 0.91, 0.90, 0.71, 0.91, and 0.99, respectively.Conclusion: The overall diagnostic performance of the US RSSs was moderate in the differentiation of indeterminate nodules.